test altFunding OpportunitiesAward ManagementComliance Review and OversightEducation and TrainingTechnology Transfer
Office of Research and Technology Management
Promoting Research, Advancing Scholarship, Fostering Innovation
Identify Funding Oportunities Proposal Development Award Management
Compliance Review and Oversight Education and Training Technology Transfer


Welcome from the Vice President for Research

CWRU researchers are among the most distinguished in the world. We have 16 Nobel Laureates among current and former faculty and alumni, 4 members of the National Academies of Sciences, 7 members of the National Academy of Engineering, and 8 members of the Institute of Medicine. We also partner with artistic and cultural institutions on a broad range of projects that make important scholarly contributions in the humanities and social sciences.

Extraordinary research requires an outstanding infrastructure. Our Office of Research & Technology Management provides support to seek out grant funding, to facilitate industrial sponsorship, and to transfer university technologies to the marketplace. This is a place for people driven to make a difference, and our office exists to help them succeed.

Contact us. We want you to see what our campus can offer.

Dr. Suzanne Rivera


Research Matters

Research Matters

Use the following link in order to view previous editions of Research Matters and Research News and Updates Research Matters Archive .




Latest News

Research Newsletter
May 14, 2015  

Vilcek Foundation

The Vilcek Foundation is seeking applicants for the 2016 Vilcek Prizes for Creative Promise in Biomedical Science. They are accepting applications from young, foreign-born researchers age 38 and under from now through June 15, 2015. Three winners will each receive a $50,000 unrestricted cash prize and will be honored at an awards ceremony in New York City in April 2016.

Application Deadline: June 15, 2015.

For more information visit the Vilcek Foundation webpage.

 
National Institutes of Health – Lasker Clinical Research Scholars

The National Institutes of Health, the nation's premier agency for biomedical and behavioral research, in partnership with the Lasker Foundation, is pleased to announce the Lasker Clinical Research Scholars Program, an historic "intramural-extramural" partnership to nurture the next generation of clinical researchers. The program supports a small number of exceptional clinical researchers in the early stages of their careers to promote their development to fully independent positions. Successful candidates are designated as Lasker Clinical Research Scholars.

Lasker Scholars receive a unique combination of NIH funding for clinical research for to 10 years. In the first phase of the program, Scholars will receive appointments for 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent budgets. In the second phase, successful Scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or the Scholar can be considered to remain as an investigator within the intramural program.

Lasker Scholars will have access to the NIH Clinical Center, the nation's largest hospital devoted entirely to clinical research. Through an arrangement with the Lasker Foundation, Scholars will have the opportunity to participate in selected activities, including attendance at the Lasker Breakfast and Award Luncheon, and participation in annual scientific meetings.

Application Deadline: August 27, 2015

For more information visit the NIH webpage.

 
Department of Defense

The Department of Defense has announced the following new funding opportunities:

Department of the Army - USAMRAA

DoD USSOCOM Broad Agency Announcement

 
Department of Health and Human Services – Food & Drug Administration

The goal of this program is to support the advancement of regulatory science that can facilitate the implementation and the assessment of emerging manufacturing technology in the pharmaceutical sector. Emerging manufacturing technology can be viewed as a technology that has the potential to modernize the pharmaceutical manufacturing body of knowledge to support more robust, predictable, and/or cost-effective processes and with which the FDA has limited review or inspection experiences, due to its relative novelty. Examples of such elements include innovative or novel (1) product manufacturing technology, such as the dosage form; (2) manufacturing process (e.g., design, scale-up, and/or commercial scale); and/or (3) testing technology.

Application Deadline: June 30 , 2015

For more information visit the Grants.Gov webpage.

 
Centers for Disease Control Prevention

The Centers for Disease Control Prevention is soliciting applications to conduct birth defects surveillance with a focus on congenital heart defects (CHDs) among individuals of all ages. The National Center on Birth Defects and Developmental Disabilities, Division of Birth Defects and Developmental Disabilities seeks to fund collaborative projects in two categories: (1) Category A: Build on existing infrastructure for population-based CHDs surveillance to (i) conduct longitudinal follow up of both adolescents and adults identified having a CHD, (ii) identify factors associated with optimal healthcare and improved outcomes, (iii) evaluate factors that impede appropriate transition from pediatric to adult care, (iv) expand surveillance activities to include the lifespan, if possible, and (v) develop pilot projects to translate public health best practices into action; and (2) Category B: Develop and implement innovative approaches for conducting population-based surveillance of CHDs in adolescents and adults, and if possible, across the lifespan, by linking existing data sources. Surveillance data will be used for descriptive epidemiology, to identify comorbidities, and examine healthcare utilization and referral to timely and appropriate services. CHDs are one of the most prevalent birth defects in the United States affecting about one percent of all births and are a leading cause of birth defect-associated infant mortality, morbidity, and healthcare costs. However, most current efforts to conduct population-based surveillance of CHDs have focused on monitoring newborns, and little data exist on the prevalence and descriptive epidemiology of CHDs beyond early childhood in the United States. Improvements in treatment of CHDs and consequently in survival have resulted in many individuals, even those affected by a very severe CHD, living into adolescence and adulthood.

Application Deadline: June 1, 2015

For more information visit the Grants.Gov website.

 

If you have news or information that you wish to have included in this update, please send it via e-mail to Tracy Wilson-Holden at tracy.wilson-holden@case.edu no later than 5 pm on the Monday of the week that the update is to be distributed. If you know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe to Case Research News, email your request to Tora Williams at tora.williams@case.edu.

Please note: At the time of this transmission, all links functioned. However, Case Research News cannot guarantee that the information will not move or be deleted.